After six decades of research, science is no longer just close to curing hepatitis B — the first drugs capable of achieving a functional cure are already here. In October 2025, China approved Pegbing, the world’s first drug designed to functionally cure chronic hepatitis B, with clinical trials showing 31.4% of patients achieving clinical cure 24 weeks after stopping all medications. Then in January 2026, pharmaceutical giant GSK announced that bepirovirsen, a first-in-class antisense oligonucleotide, met its primary endpoint in two massive Phase III trials spanning over 1,800 patients across 29 countries. For the roughly 296 million people worldwide living with chronic hepatitis B — a virus first identified by Nobel laureate Baruch S. Blumberg in 1963 — these breakthroughs represent the most significant therapeutic shift in the disease’s history. For readers of a brain health and dementia care site, this matters more than you might expect.
Chronic hepatitis B drives liver disease, and the liver plays a critical role in clearing toxins that can damage the brain. Hepatic encephalopathy, a condition where a failing liver allows ammonia and other waste products to accumulate in the bloodstream, is a well-recognized cause of cognitive decline, confusion, and even coma. Cirrhosis from untreated hepatitis B is one of its leading triggers. Beyond that, the systemic inflammation caused by chronic viral hepatitis has been linked in epidemiological research to elevated dementia risk. A cure for hepatitis B is not just a liver story — it is potentially a brain health story too. This article covers why hepatitis B has resisted a cure for so long, what the new drugs actually do, the pipeline of treatments now in development, the massive new research funding being deployed, and what all of this means for aging populations vulnerable to both liver disease and cognitive decline.
Table of Contents
- Why Has Curing Hepatitis B Taken More Than 60 Years?
- Bepirovirsen — How GSK’s Breakthrough Drug Attacks the Virus on Multiple Fronts
- Pegbing — China’s Pioneering Approval and What It Means Globally
- The Emerging Pipeline — From siRNA to Repurposed Cancer Drugs
- The Liver-Brain Connection — Why a Hepatitis B Cure Matters for Dementia Prevention
- A $24 Million Global Push — New Research Funding Targets the Hardest Cases
- What Comes Next — The Road to WHO’s 2030 Elimination Goals
- Conclusion
- Frequently Asked Questions
Why Has Curing Hepatitis B Taken More Than 60 Years?
The hepatitis B virus is an extraordinarily stubborn pathogen. Unlike hepatitis C, which was effectively cured with direct-acting antivirals introduced in the 2010s, hepatitis B embeds itself into the DNA of liver cells through a structure called covalently closed circular DNA, or cccDNA. This viral reservoir acts like a hidden blueprint, continuously producing new viral proteins even when the virus itself is suppressed. Current standard-of-care drugs — nucleoside analogues like tenofovir and entecavir — can suppress viral replication effectively, but they cannot eliminate that embedded reservoir. The result is that most patients must take daily pills for life, and if they stop, the virus roars back. Achieving what researchers call a “functional cure,” defined as sustained loss of hepatitis B surface antigen (HBsAg) after stopping treatment, happens in only about 1% of patients on existing therapies. To put that 1% figure in context, consider a clinic in sub-Saharan Africa managing 500 chronic hepatitis B patients on tenofovir.
Statistically, only about five of those patients would ever clear HBsAg and be able to safely stop treatment. The other 495 face a lifetime of daily medication, regular monitoring, and the ongoing risk of cirrhosis and liver cancer. Hepatitis B still causes an estimated 1.1 million deaths per year globally, primarily from these complications, with over 1.5 million new preventable infections occurring annually. The virus was identified in 1963, the vaccine arrived in the 1980s, and effective suppressive drugs came in the late 1990s and 2000s — but a true cure remained out of reach until now. The comparison with hepatitis C is instructive but also misleading. Hepatitis C is an RNA virus that does not integrate into host cell DNA, making it far more vulnerable to direct-acting antivirals. Hepatitis B’s DNA integration and its cccDNA reservoir mean that any cure strategy must either destroy that reservoir, silence it permanently, or train the immune system to control the virus without ongoing medication. That is precisely what the new generation of drugs attempts to do.
Bepirovirsen — How GSK’s Breakthrough Drug Attacks the Virus on Multiple Fronts
On January 7, 2026, GSK announced positive results from B-Well 1 and B-Well 2, two pivotal Phase III trials that together enrolled over 1,800 patients across 29 countries. Bepirovirsen, developed in partnership with Ionis Pharmaceuticals, is a first-in-class antisense oligonucleotide — a short synthetic strand of modified DNA designed to bind to viral RNA and trigger its destruction. But bepirovirsen does more than silence RNA. It has a triple mechanism of action: it destroys viral RNA, inhibits viral DNA replication, suppresses HBsAg production, and stimulates the patient’s own immune response against the virus. The trials met their primary endpoint, with functional cure rates statistically significantly higher in patients receiving bepirovirsen plus standard of care compared to standard of care alone. GSK plans to submit for regulatory approval, with full data to be presented at an upcoming scientific congress. The earlier Phase 2b data gives a sense of the magnitude of improvement. Weekly injections of 300 mg bepirovirsen for 24 weeks achieved sustained HBsAg and HBV DNA loss in 9 to 10% of participants. That may sound modest until you recall the baseline: existing drugs achieve functional cure in roughly 1% of patients.
Bepirovirsen represents approximately a tenfold improvement. However, this also means that even with bepirovirsen, the majority of treated patients will not achieve functional cure. The drug is a major advance, not a universal solution. Patients with lower baseline HBsAg levels tend to respond better, which means careful patient selection will be critical to maximizing real-world outcomes. There is a practical limitation worth noting. Bepirovirsen is an injectable therapy requiring weekly subcutaneous injections over a treatment course of at least 24 weeks. For patients in well-resourced healthcare systems, this is manageable. But for the regions bearing the heaviest hepatitis B burden — sub-Saharan Africa, Southeast Asia, parts of the Pacific Islands — weekly injections pose logistical challenges that daily oral pills do not. If bepirovirsen wins regulatory approval, access and delivery infrastructure will determine whether it reaches the patients who need it most.
Pegbing — China’s Pioneering Approval and What It Means Globally
China carries a disproportionate share of the global hepatitis B burden, with approximately 75 million chronic patients. So it is fitting that the world’s first approved functional cure drug emerged there. In October 2025, Chinese regulators approved Pegbing, developed by Amoytop Biotech in Xiamen, for use in combination with antivirals to achieve sustained HBsAg clearance in adults with chronic hepatitis B. The clinical trial results were striking: 31.4% of patients receiving Pegbing plus antiviral combination therapy achieved clinical cure 24 weeks after discontinuing all medications. Compare that to the 1% functional cure rate with conventional nucleoside analogues, and the scale of the advance becomes clear. Pegbing is an injectable drug, and its approval is currently limited to China. For the rest of the world, access depends on whether Amoytop pursues regulatory submissions in other countries and whether international bodies like the WHO add it to prequalification lists.
There is also a critical caveat: Pegbing’s impressive 31.4% cure rate was achieved in combination with existing antivirals, not as monotherapy. Patients considering this treatment would still need to be on background antiviral therapy, and the optimal combination regimens and treatment durations are still being refined. Furthermore, not all patient populations were equally represented in the trials, so how well these results translate to patients with advanced cirrhosis or those co-infected with HIV remains an open question. For older adults — a population this site’s readers care deeply about — the Pegbing approval raises a particular consideration. Many elderly patients with chronic hepatitis B have been on suppressive therapy for years or even decades. Switching to a cure-oriented regimen involves a period of immune activation that can cause liver inflammation flares. In younger, healthier patients, this is generally manageable. In older adults with reduced hepatic reserve or comorbidities including early cognitive decline, the risk-benefit calculus requires careful individualized assessment.
The Emerging Pipeline — From siRNA to Repurposed Cancer Drugs
Bepirovirsen and Pegbing are the furthest along, but they are not alone. The hepatitis B cure pipeline is now deeper than at any point in history. AusperBio reported in December 2025 that its drug AHB-137 achieved a 30% functional cure rate at week 72 in Phase 2a monotherapy trials among patients with baseline HBsAg levels between 100 and 1,000 IU/mL. That this was achieved with monotherapy — no background antiviral needed — is particularly notable, as it suggests a simpler treatment approach may be possible for certain patient subgroups. On the preclinical side, a small interfering RNA called KC13-M2G2, published in Nature Communications in 2025, triggered rapid and sustained loss of HBsAg and HBV DNA in mouse models, reportedly outperforming bepirovirsen in head-to-head preclinical comparisons. Meanwhile, researchers at Memorial Sloan Kettering, Weill Cornell Medicine, and The Rockefeller University reported in February 2025 that they had identified a vulnerability in how hepatitis B infects liver cells and successfully disrupted the infection using a compound already in clinical trials for cancer.
Repurposing existing cancer drugs for hepatitis B could dramatically accelerate the path to approval, since safety data in humans already exists. The tradeoff across this pipeline is between efficacy and simplicity. Combination regimens like Pegbing plus antivirals show the highest cure rates but are more complex and expensive. Monotherapy approaches like AHB-137 are simpler but may work only in patients with lower viral burdens. siRNA approaches like KC13-M2G2 are still years from human trials. And repurposed cancer drugs, while scientifically elegant, may carry side effect profiles that limit their use in the broader hepatitis B population. Patients and clinicians will eventually face a menu of options, each with distinct advantages and drawbacks, rather than a single magic bullet.
The Liver-Brain Connection — Why a Hepatitis B Cure Matters for Dementia Prevention
Chronic hepatitis B does its most visible damage in the liver, but the downstream effects on the brain are real and underappreciated. Hepatic encephalopathy — cognitive impairment caused by the liver’s inability to clear ammonia and other neurotoxins from the blood — affects up to 70% of patients with cirrhosis at some point in their disease course. Symptoms range from subtle attention deficits and slowed processing speed, easily mistaken for early dementia, to full-blown confusion, personality changes, and coma. For families already navigating a dementia diagnosis, an unrecognized hepatic encephalopathy component can mean that treatable cognitive decline goes unaddressed. Beyond hepatic encephalopathy, chronic viral hepatitis drives persistent systemic inflammation, which epidemiological studies have associated with increased risk of Alzheimer’s disease and vascular dementia.
The mechanisms are not fully established, but chronic inflammation accelerates blood-brain barrier breakdown, promotes neuroinflammation, and may hasten amyloid and tau pathology. A functional cure for hepatitis B would eliminate one source of that chronic inflammatory burden. A limitation worth stating plainly: curing hepatitis B will not reverse existing dementia or undo cirrhosis that has already developed. The benefit is preventive, not restorative. For the millions of people in their 40s and 50s living with chronic hepatitis B today, achieving functional cure before liver disease progresses could meaningfully reduce their risk of hepatic encephalopathy and inflammation-driven cognitive decline decades later. But for patients who already have advanced cirrhosis, the brain health benefits of viral cure are less certain, and liver transplant evaluation may be more appropriate.
A $24 Million Global Push — New Research Funding Targets the Hardest Cases
On March 10, 2026, Johns Hopkins Medicine announced it will lead a $24 million, five-year multinational consortium funded by the National Institutes of Health and NIAID to find a hepatitis B cure. The consortium spans Brazil, India, Senegal, Uganda, and the United States, and its first-year goal is to enroll 450 people co-infected with HIV and chronic hepatitis B alongside 225 people with chronic hepatitis B alone.
This focus on HIV co-infection is critical because roughly 10% of people living with HIV in sub-Saharan Africa also carry hepatitis B, and co-infected patients are often excluded from cure-oriented clinical trials despite facing worse outcomes than those with hepatitis B alone. This investment signals that the global research community recognizes the gap between breakthrough drugs developed in wealthy countries and the populations that bear the greatest disease burden. Whether the new drugs coming to market will be priced accessibly enough for low- and middle-income countries remains one of the most consequential unanswered questions in this space.
What Comes Next — The Road to WHO’s 2030 Elimination Goals
The WHO has set targets of 90% vaccination coverage and 80% treatment of eligible patients by 2030. Current reality falls short: global birth-dose vaccination coverage sits at just 46%, and the vast majority of the 296 million people living with chronic hepatitis B worldwide are neither diagnosed nor on treatment. The new functional cure drugs change the treatment equation but not the diagnosis and access equation. A drug that cures hepatitis B in a clinical trial does nothing for the patient in rural Uganda who does not know they are infected.
Looking ahead, the most optimistic realistic scenario is that by 2030, multiple functional cure options will be approved and available in high-income countries, with combination regimens pushing cure rates above 30%. The harder problem — screening, diagnosing, and treating the hundreds of millions of people in low-resource settings — will require sustained political commitment, generic manufacturing agreements, and the kind of global health infrastructure that took decades to build for HIV. The science, at last, has delivered. Now the systems must follow.
Conclusion
After 60 years, the hepatitis B cure is no longer theoretical. Pegbing is approved in China with a 31.4% functional cure rate. Bepirovirsen has succeeded in Phase III trials across 29 countries. AHB-137 shows 30% cure rates as monotherapy. Preclinical candidates like KC13-M2G2 and repurposed cancer compounds are advancing through the pipeline.
And a $24 million NIH-funded consortium is targeting the hardest-to-reach patient populations. For the 296 million people living with chronic hepatitis B, these developments represent the most significant therapeutic shift since the vaccine was introduced in the 1980s. For those focused on brain health and dementia prevention, the relevance is direct. Chronic hepatitis B drives liver disease, which in turn causes hepatic encephalopathy and systemic inflammation — both recognized contributors to cognitive decline. Eliminating the virus before it causes irreversible liver damage is, in a very real sense, a form of dementia prevention. If you or someone you care for has chronic hepatitis B, now is the time to talk with a hepatologist about whether newer cure-oriented treatments may be appropriate, and to ensure that liver health is part of every conversation about long-term brain health.
Frequently Asked Questions
Is there now a complete cure for hepatitis B?
Not a sterilizing cure that eliminates every trace of viral DNA, but functional cures — where the virus is durably suppressed and treatment can be stopped — are now achievable. Pegbing, approved in China in October 2025, achieved functional cure in 31.4% of patients in combination therapy trials. Bepirovirsen showed positive Phase III results in January 2026. These represent a dramatic improvement over the roughly 1% functional cure rate seen with existing drugs.
Can hepatitis B cause dementia or cognitive problems?
Yes, indirectly. When chronic hepatitis B progresses to cirrhosis, the liver loses its ability to clear toxins like ammonia from the blood. This causes hepatic encephalopathy, which can produce symptoms ranging from subtle attention and memory problems to severe confusion. Chronic inflammation from hepatitis B has also been associated in research studies with elevated dementia risk, though the causal mechanisms are still being studied.
How is bepirovirsen different from current hepatitis B drugs?
Current drugs like tenofovir and entecavir suppress viral replication but do not clear the virus. Patients must take them daily for life. Bepirovirsen is an antisense oligonucleotide that destroys viral RNA, inhibits viral DNA replication, suppresses HBsAg production, and stimulates the immune system. In Phase 2b trials, it achieved functional cure in 9 to 10% of patients after a defined treatment course, compared to about 1% with standard therapy.
Is Pegbing available outside of China?
As of early 2026, Pegbing is approved only in China. Whether Amoytop Biotech will seek regulatory approval in other countries or through the WHO prequalification process has not been publicly announced. Patients outside China should discuss emerging treatment options with their hepatologists.
Should elderly patients with chronic hepatitis B consider these new treatments?
Potentially, but with caution. Cure-oriented regimens can cause liver inflammation flares during immune activation phases. In older adults with reduced liver reserve, other chronic conditions, or cognitive impairment, the risks and benefits need individualized assessment by a specialist. The preventive benefit is greatest for patients who have not yet developed advanced liver disease.
What is the WHO’s goal for hepatitis B elimination?
The WHO targets 90% hepatitis B vaccination coverage and treatment of 80% of eligible patients by 2030. Currently, global birth-dose vaccination coverage is only 46%, and most of the estimated 296 million people living with chronic hepatitis B are undiagnosed and untreated.
